Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fenretinide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Laurent Pharmaceuticals reaches agreement with US Cystic Fibrosis Foundation to increase Development Award to $US 5M
    Laurent Pharmaceuticals reaches agreement with US Cystic Fibrosis Foundation to increase Development Award to $US 5M

    14 Mar 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/laurent-pharmaceuticals-reaches-agreement-with-us-cystic-fibrosis-foundation-to-increase-development-award-to-us-5m-676835603.html

    PR NEWSWIRE
    14 Mar 2018
    Share Share
    Laurent Pharmaceuticals Receives FDA and Health Canada Clearance to Initiate APPLAUD Phase 2 Clinical Study of LAU-7b for the Treatment of Cystic Fibrosis
    Laurent Pharmaceuticals Receives FDA and Health Canada Clearance to Initiate APPLAUD Phase 2 Clinical Study of LAU-7b for the Treatment of Cystic Fibrosis

    19 Apr 2017

    // PRESS RELEASE

    http://www.laurentpharma.com/news/63-laurent-pharmaceuticals-receives-fda-and-health-canada-clearance-to-initiate-applaud-phase-2-clinical-study-of-lau-7b-for-the-treatment-of-cystic-fibrosis.html

    PRESS RELEASE
    19 Apr 2017
    Share Share
    Design of controlled release PLGA microspheres for hydrophobic fenretinide
    Design of controlled release PLGA microspheres for hydrophobic fenretinide

    23 May 2016

    // PHARMA-EXCIPIENTS

    http://www.pharma-excipients.ch/2016/05/24/design-of-controlled-release-plga-microspheres-for-hydrophobic-fenretinide/

    PHARMA-EXCIPIENTS
    23 May 2016
    Share Share